MNKD: Strong early demand for ReadyFlow and focused pipeline execution set the stage for growth
Three major catalysts—Afrezza pediatric approval, FUROSCIX ReadyFlow launch, and MNKD-201 phase I-B data—are driving focus on commercial execution and pipeline expansion. Early ReadyFlow demand is strong, Afrezza pediatric launch is concentrated in academic centers, and MNKD-201 phase II aims for 2…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.